Collaboration and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Collaboration and Licensing Agreements

Schedule of revenue by licensees

The revenues recorded for the three months ended March 31, 2020 were earned principally from the following licensees (in millions):

	Three Months Ended
	March 31,
	2020		2019
Aimmune	$	9.6	$	—
Alexion		3.3		—
Astellas		0.3		—
Genentech		0.7		112.0
Gilead		6.0		—
MorphoSys		12.5		—
Total	$	32.4	$	112.0

Schedule of disaggregation of revenue

The table below summarizes the disaggregation of revenue recorded for the three months ended March 31, 2020 (in millions):

	Three Months Ended
	March 31,
	2020		2019
Research collaboration	$	1.0	$	0.3
Milestone		12.5		—
Licensing		15.6		111.7
Royalties		3.3		—
Total	$	32.4	$	112.0